301263 泰恩康
交易中 03-06 10:35:06
资讯
新帖
简况
泰恩康(301263)披露全资子公司五款药品中选国家集采药品接续采购公告,3月2日股价下跌3.8%
证券之星 · 03-02
泰恩康(301263)披露全资子公司五款药品中选国家集采药品接续采购公告,3月2日股价下跌3.8%
泰恩康(301263)披露2026年员工持股计划证券账户开立公告,2月26日股价下跌1.61%
证券之星 · 02-26
泰恩康(301263)披露2026年员工持股计划证券账户开立公告,2月26日股价下跌1.61%
泰恩康(301263)披露2026年员工持股计划第一次持有人会议决议公告,2月25日股价上涨1.38%
证券之星 · 02-25
泰恩康(301263)披露2026年员工持股计划第一次持有人会议决议公告,2月25日股价上涨1.38%
泰恩康(301263)披露2026年第一次临时股东会决议公告,2月24日股价下跌0.38%
证券之星 · 02-24
泰恩康(301263)披露2026年第一次临时股东会决议公告,2月24日股价下跌0.38%
泰恩康(301263)披露全资子公司收到米诺地尔搽剂药品注册证书的公告,2月6日股价下跌2.12%
证券之星 · 02-06
泰恩康(301263)披露全资子公司收到米诺地尔搽剂药品注册证书的公告,2月6日股价下跌2.12%
泰恩康(301263)股东郑汉杰、孙伟文合计质押800万股,占总股本1.88%
证券之星 · 02-02
泰恩康(301263)股东郑汉杰、孙伟文合计质押800万股,占总股本1.88%
泰恩康(301263)披露全资子公司利多卡因丙胺卡因气雾剂获药品注册受理通知书,1月30日股价下跌1.44%
证券之星 · 01-30
泰恩康(301263)披露全资子公司利多卡因丙胺卡因气雾剂获药品注册受理通知书,1月30日股价下跌1.44%
泰恩康最新公告:全资子公司收到尼莫地平注射液药品注册证书
证券之星 · 01-30
泰恩康最新公告:全资子公司收到尼莫地平注射液药品注册证书
【私募调研记录】青鼎资产调研泰恩康
证券之星 · 01-30
【私募调研记录】青鼎资产调研泰恩康
【私募调研记录】恒复投资调研泰恩康
证券之星 · 01-30
【私募调研记录】恒复投资调研泰恩康
【私募调研记录】域秀资产调研泰恩康
证券之星 · 01-30
【私募调研记录】域秀资产调研泰恩康
泰恩康最新公告:预计2025年净利润同比减少67.66%-76.90%
证券之星 · 01-28
泰恩康最新公告:预计2025年净利润同比减少67.66%-76.90%
泰恩康最新公告:控股子公司CKBA乳膏申报儿童白癜风获得药物临床试验批准通知书
证券之星 · 01-22
泰恩康最新公告:控股子公司CKBA乳膏申报儿童白癜风获得药物临床试验批准通知书
泰恩康(301263)披露控股股东、实际控制人部分股份质押公告,1月21日股价下跌0.52%
证券之星 · 01-21
泰恩康(301263)披露控股股东、实际控制人部分股份质押公告,1月21日股价下跌0.52%
泰恩康(301263)披露控股股东、实际控制人部分股份质押的公告,1月15日股价下跌0.13%
证券之星 · 01-15
泰恩康(301263)披露控股股东、实际控制人部分股份质押的公告,1月15日股价下跌0.13%
股市必读:泰恩康(301263)1月8日董秘有最新回复
证券之星 · 01-09
股市必读:泰恩康(301263)1月8日董秘有最新回复
泰恩康:CKBA白癜风及玫瑰痤疮临床进展
证券之星 · 01-08
泰恩康:CKBA白癜风及玫瑰痤疮临床进展
泰恩康(301263)披露聘任高级管理人员公告,12月26日股价下跌1.5%
证券之星 · 2025-12-26
泰恩康(301263)披露聘任高级管理人员公告,12月26日股价下跌1.5%
泰恩康最新公告:全资子公司收到非那雄胺他达拉非胶囊药品注册证书
证券之星 · 2025-12-22
泰恩康最新公告:全资子公司收到非那雄胺他达拉非胶囊药品注册证书
泰恩康(301263)披露控股股东、实际控制人部分股份解除质押公告,12月19日股价上涨2.21%
证券之星 · 2025-12-19
泰恩康(301263)披露控股股东、实际控制人部分股份解除质押公告,12月19日股价上涨2.21%
加载更多
公司概况
公司名称:
广东泰恩康医药股份有限公司
所属行业:
批发业
上市日期:
2022-03-29
主营业务:
广东泰恩康医药股份有限公司的主营业务是代理运营及研发、生产、销售医药产品、医疗器械、卫生材料并提供医药技术服务与技术转让等。公司的主要产品是盐酸达泊西汀片、他达拉非片、枸橼酸西地那非口崩片、和胃整肠丸、沃丽汀、风油精、六味地黄丸、藿香正气丸、奥硝唑注射液。公司自主研发的“爱廷玖”盐酸达泊西汀片为首个国产PE用药,2020年8月正式投放市场,目前在达泊西汀院外渠道市场稳居头部地位,尤其在线下零售市场形成显著品牌优势。
发行价格:
19.93
{"stockData":{"symbol":"301263","market":"SZ","secType":"STK","nameCN":"泰恩康","latestPrice":29.49,"timestamp":1772764506000,"preClose":28.91,"halted":0,"volume":1406500,"delay":0,"changeRate":0.0201,"floatShares":304000000,"shares":425000000,"eps":0.0548,"marketStatus":"交易中","change":0.58,"latestTime":"03-06 10:35:06","open":28.8,"high":29.8,"low":28.8,"amount":41515300,"amplitude":0.0346,"askPrice":29.5,"askSize":15,"bidPrice":29.47,"bidSize":15,"shortable":0,"etf":0,"ttmEps":0.0548,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1772767800000},"marketStatusCode":2,"adr":0,"adjPreClose":28.91,"symbolType":"stock","openAndCloseTimeList":[[1772760600000,1772767800000],[1772773200000,1772780400000]],"highLimit":31.8,"lowLimit":26.02,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":425497500,"isCdr":false,"pbRate":7.09,"roa":"--","peRate":538.138686,"roe":"1.79%","epsLYR":0.26,"committee":0.189711,"marketValue":12548000000,"turnoverRate":0.0046,"status":0,"floatMarketCap":8953000000},"requestUrl":"/m/hq/s/301263","defaultTab":"news","newsList":[{"id":"2616355236","title":"泰恩康(301263)披露全资子公司五款药品中选国家集采药品接续采购公告,3月2日股价下跌3.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616355236","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616355236?lang=zh_cn&edition=full","pubTime":"2026-03-02 22:52","pubTimestamp":1772463136,"startTime":"0","endTime":"0","summary":"截至2026年3月2日收盘,泰恩康报收于30.09元,较前一交易日下跌3.8%,最新总市值为128.03亿元。公司于2026年3月2日发布《关于全资子公司部分药品中选国家集采药品接续采购的公告》。公告显示,泰恩康全资子公司山东华铂凯盛生物科技有限公司参加国家组织集采药品协议期满品种接续采购,其五款药品包括他达拉非片、盐酸达泊西汀片、盐酸普拉克索缓释片、阿加曲班注射液和奥硝唑注射液成功中选。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200040165.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2614023325","title":"泰恩康(301263)披露2026年员工持股计划证券账户开立公告,2月26日股价下跌1.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614023325","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614023325?lang=zh_cn&edition=full","pubTime":"2026-02-26 22:43","pubTimestamp":1772116991,"startTime":"0","endTime":"0","summary":"公司于近日披露《关于2026年员工持股计划实施进展的公告》。公告显示,广东泰恩康医药股份有限公司于2026年1月28日及2月13日召开董事会及临时股东会,审议通过2026年员工持股计划相关议案;2026年2月13日,董事会审议通过草案修订稿;2026年2月26日,该员工持股计划在中国证券登记结算有限责任公司开立证券账户,账户名称为“广东泰恩康医药股份有限公司-2026年员工持股计划”,账户号码为0899531730。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600037434.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","BK0250","301263"],"gpt_icon":0},{"id":"2614503371","title":"泰恩康(301263)披露2026年员工持股计划第一次持有人会议决议公告,2月25日股价上涨1.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614503371","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614503371?lang=zh_cn&edition=full","pubTime":"2026-02-25 22:30","pubTimestamp":1772029848,"startTime":"0","endTime":"0","summary":"公司于2026年2月25日发布《2026年员工持股计划第一次持有人会议决议公告》。公告显示,广东泰恩康医药股份有限公司于2026年2月25日召开2026年员工持股计划第一次持有人会议,会议以通讯方式举行,应到持有人166名,实际参会166名,代表份额3,360.8048万份,占总份额的100%。会议同时通过授权管理委员会办理员工持股计划相关事宜的议案,授权事项包括召集持有人会议、日常管理、行使股东权利、权益处置、减持安排等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500038218.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2613954718","title":"泰恩康(301263)披露2026年第一次临时股东会决议公告,2月24日股价下跌0.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613954718","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613954718?lang=zh_cn&edition=full","pubTime":"2026-02-24 19:18","pubTimestamp":1771931893,"startTime":"0","endTime":"0","summary":"截至2026年2月24日收盘,泰恩康报收于31.8元,较前一交易日下跌0.38%,最新总市值为135.31亿元。该股当日开盘32.3元,最高32.55元,最低31.66元,成交额达9441.55万元,换手率为0.98%。公司于近日披露《2026年第一次临时股东会决议公告》。各项议案均获得出席会议股东所持有效表决权的多数同意,表决结果合法有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400038809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2609926591","title":"泰恩康(301263)披露全资子公司收到米诺地尔搽剂药品注册证书的公告,2月6日股价下跌2.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609926591","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609926591?lang=zh_cn&edition=full","pubTime":"2026-02-06 22:13","pubTimestamp":1770387180,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘,泰恩康报收于32.3元,较前一交易日下跌2.12%,最新总市值为137.44亿元。公司于2026年2月6日发布《关于全资子公司收到米诺地尔搽剂药品注册证书的公告》。公告显示,广东泰恩康医药股份有限公司全资子公司山东华铂凯盛生物科技有限公司近日收到国家药品监督管理局签发的米诺地尔搽剂《药品注册证书》,批准其境内生产药品注册上市许可。米诺地尔搽剂为外用脱发治疗药物,目前国内已有31家企业取得该品种注册批件。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600040892.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"gpt_icon":0},{"id":"2608850017","title":"泰恩康(301263)股东郑汉杰、孙伟文合计质押800万股,占总股本1.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608850017","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608850017?lang=zh_cn&edition=full","pubTime":"2026-02-02 18:39","pubTimestamp":1770028775,"startTime":"0","endTime":"0","summary":"证券之星消息,泰恩康2月2日公开信息显示,股东郑汉杰、孙伟文向华能贵诚信托有限公司合计质押800.0万股,占总股本1.88%。质押详情见下表:截止本公告日,股东郑汉杰已累计质押股份3500.0万股,占其持股总数的39.6%,股东孙伟文已累计质押股份2377.0万股,占其持股总数的35.9%。泰恩康主营业务:代理运营及研发、生产、销售医药产品、医疗器械、卫生材料并提供医药技术服务与技术转让等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200028870.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"gpt_icon":0},{"id":"2607013794","title":"泰恩康(301263)披露全资子公司利多卡因丙胺卡因气雾剂获药品注册受理通知书,1月30日股价下跌1.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607013794","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607013794?lang=zh_cn&edition=full","pubTime":"2026-01-30 17:30","pubTimestamp":1769765443,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘,泰恩康报收于32.15元,较前一交易日下跌1.44%,最新总市值为136.8亿元。该股当日开盘32.62元,最高33.0元,最低32.03元,成交额达1.08亿元,换手率为1.1%。公司于近日披露公告,广东泰恩康医药股份有限公司全资子公司山东华铂凯盛生物科技有限公司近日收到国家药监局签发的利多卡因丙胺卡因气雾剂境内生产药品注册上市许可申请《受理通知书》。该事项对公司近期业绩无直接影响,最终审评审批结果存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000030714.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"gpt_icon":0},{"id":"2607013218","title":"泰恩康最新公告:全资子公司收到尼莫地平注射液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2607013218","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607013218?lang=zh_cn&edition=full","pubTime":"2026-01-30 17:22","pubTimestamp":1769764921,"startTime":"0","endTime":"0","summary":"泰恩康(301263.SZ)公告称,公司全资子公司山东华铂凯盛生物科技有限公司收到国家药品监督管理局签发的尼莫地平注射液《药品注册证书》。该产品为化学药品4类,规格为50ml:10mg,上市许可持有人为山东华铂凯盛生物科技有限公司。尼莫地平注射液具有抗缺血和抗血管收缩的作用,可改善蛛网膜下腔出血后的脑血管痉挛和急性脑血管病恢复期的血液循环。目前国内有44家企业获得该药品注册批件。该产品未来销售情况受行业政策、市场环境等因素影响,具有不确定性。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000030098.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2607050034","title":"【私募调研记录】青鼎资产调研泰恩康","url":"https://stock-news.laohu8.com/highlight/detail?id=2607050034","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607050034?lang=zh_cn&edition=full","pubTime":"2026-01-30 08:11","pubTimestamp":1769731895,"startTime":"0","endTime":"0","summary":"根据市场公开信息及1月29日披露的机构调研信息,知名私募青鼎资产近期对1家上市公司进行了调研,相关名单如下:1)泰恩康 调研纪要:随着核心品种陆续获批上市,公司2026年收入将有明显增长,2027-2028年预计爆发性增长。和胃整肠丸已开展品牌推广,拓展线上及第三终端渠道,预计2026年一、二季度销售良好。公司计划今年启动美国FDA的IND申报,探索海外市场。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2026013000007033.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2607032050","title":"【私募调研记录】恒复投资调研泰恩康","url":"https://stock-news.laohu8.com/highlight/detail?id=2607032050","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607032050?lang=zh_cn&edition=full","pubTime":"2026-01-30 08:11","pubTimestamp":1769731892,"startTime":"0","endTime":"0","summary":"根据市场公开信息及1月29日披露的机构调研信息,知名私募恒复投资近期对1家上市公司进行了调研,相关名单如下:1)泰恩康 调研纪要:随着核心品种陆续获批上市,公司2026年收入将有明显增长,2027-2028年预计爆发性增长。和胃整肠丸已开展品牌推广,拓展线上及第三终端渠道,预计2026年一、二季度销售良好。公司计划今年启动美国FDA的IND申报,探索海外市场。机构简介:上海恒复投资管理有限公司于2008年9月8日成立,注册资本2000万元人民币。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2026013000007024.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"gpt_icon":0},{"id":"2607050075","title":"【私募调研记录】域秀资产调研泰恩康","url":"https://stock-news.laohu8.com/highlight/detail?id=2607050075","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607050075?lang=zh_cn&edition=full","pubTime":"2026-01-30 08:11","pubTimestamp":1769731890,"startTime":"0","endTime":"0","summary":"根据市场公开信息及1月29日披露的机构调研信息,知名私募域秀资产近期对1家上市公司进行了调研,相关名单如下:1)泰恩康 调研纪要:随着核心品种陆续获批上市,公司2026年收入将有明显增长,2027-2028年预计爆发性增长。和胃整肠丸已开展品牌推广,拓展线上及第三终端渠道,预计2026年一、二季度销售良好。公司计划今年启动美国FDA的IND申报,探索海外市场。域秀资本致力于为客户提供多策略、优质的资产管理方案,持续为客户创造最大价值。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2026013000007021.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"gpt_icon":0},{"id":"2606435977","title":"泰恩康最新公告:预计2025年净利润同比减少67.66%-76.90%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606435977","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606435977?lang=zh_cn&edition=full","pubTime":"2026-01-28 23:40","pubTimestamp":1769614837,"startTime":"0","endTime":"0","summary":"泰恩康(301263.SZ)公告称,泰恩康预计2025年归属于上市公司股东的净利润为2,500万元-3,500万元,比上年同期下降67.66%-76.90%。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800043863.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263"],"gpt_icon":0},{"id":"2605495079","title":"泰恩康最新公告:控股子公司CKBA乳膏申报儿童白癜风获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2605495079","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605495079?lang=zh_cn&edition=full","pubTime":"2026-01-22 20:21","pubTimestamp":1769084473,"startTime":"0","endTime":"0","summary":"泰恩康公告称,公司控股子公司江苏博创园生物医药科技有限公司收到国家药品监督管理局签发的《药物临床试验批准通知书》,同意博创园提交的CKBA乳膏联合窄谱中波紫外线在2-12岁儿童非节段型白癜风受试者中的安全耐受性、疗效和药代动力学特征的多中心、随机、双盲、安慰剂对照II期临床研究申请。此次儿童白癜风II期临床试验申请获批后,公司将快速推进相关试验,争取CKBA乳膏获批成为全球首个治疗2-12岁儿童白癜风的1类创新药。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200037326.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"gpt_icon":0},{"id":"2605756488","title":"泰恩康(301263)披露控股股东、实际控制人部分股份质押公告,1月21日股价下跌0.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605756488","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605756488?lang=zh_cn&edition=full","pubTime":"2026-01-21 22:14","pubTimestamp":1769004859,"startTime":"0","endTime":"0","summary":"近日,广东泰恩康医药股份有限公司发布公告,公司控股股东、实际控制人孙伟文女士将其持有的8,470,000股公司股份质押给西藏信托有限公司,占其所持股份比例12.79%,占公司总股本比例1.99%,质押用途为个人资金需要。本次质押后,孙伟文累计质押股份21,770,000股,占其所持股份比例32.88%。郑汉杰及其一致行动人合计持有公司36.33%股份,累计质押股份57,270,000股,占其持股总数的37.05%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100040714.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"gpt_icon":0},{"id":"2603986727","title":"泰恩康(301263)披露控股股东、实际控制人部分股份质押的公告,1月15日股价下跌0.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603986727","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603986727?lang=zh_cn&edition=full","pubTime":"2026-01-15 22:39","pubTimestamp":1768487951,"startTime":"0","endTime":"0","summary":"截至2026年1月15日收盘,泰恩康报收于30.51元,较前一交易日下跌0.13%,最新总市值为129.82亿元。公司近日发布公告称,控股股东、实际控制人孙伟文女士于2026年1月14日将其持有的公司股份合计7,800,000股质押给西藏信托有限公司,占其所持股份比例11.78%,占公司总股本比例1.83%,质押用途为个人资金需要。本次质押后,孙伟文累计质押股份13,300,000股,占其所持股份20.09%。公告强调,本次质押不影响公司控制权,不存在被强制平仓风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500041207.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2602111391","title":"股市必读:泰恩康(301263)1月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2602111391","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602111391?lang=zh_cn&edition=full","pubTime":"2026-01-09 01:24","pubTimestamp":1767893051,"startTime":"0","endTime":"0","summary":"截至2026年1月8日收盘,泰恩康报收于31.06元,上涨8.22%,换手率4.08%,成交量12.39万手,成交额3.82亿元。董秘最新回复投资者: 请问公司设立的欧洲子公司位于哪个国家?②针对2-12 岁儿童白癜风适应症,II期临床试验申请已获药监局受理,如获批公司将及时对外披露。上述事项如有重大进展,公司将根据相关法律法规及时履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900000950.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2601566993","title":"泰恩康:CKBA白癜风及玫瑰痤疮临床进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2601566993","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601566993?lang=zh_cn&edition=full","pubTime":"2026-01-08 15:36","pubTimestamp":1767857771,"startTime":"0","endTime":"0","summary":"投资者提问:近期国家不断出台利好医药行业特别是支持创新药的各项政策,能否简要介绍一下ckba治疗成人、2-12岁儿童白癜风以及玫瑰痤疮的最新进展?③CKBA已取得玫瑰痤疮适应症II/III期无缝适应性临床试验批件,公司正在积极筹备伦理审核、受试者入组等工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800019230.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2594329423","title":"泰恩康(301263)披露聘任高级管理人员公告,12月26日股价下跌1.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594329423","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594329423?lang=zh_cn&edition=full","pubTime":"2025-12-26 22:44","pubTimestamp":1766760257,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘,泰恩康报收于28.3元,较前一交易日下跌1.5%,最新总市值为120.42亿元。该股当日开盘28.62元,最高28.83元,最低28.16元,成交额达9725.61万元,换手率为1.13%。根据公司近日发布的公告,广东泰恩康医药股份有限公司于2025年12月26日召开第五届董事会第十二次会议,审议通过聘任郑锐涵先生为公司副总经理,协助总经理分管全面日常工作;聘任林姿丽女士为公司副总经理,分管总经办、业务部、质管部等部门。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600036775.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"gpt_icon":0},{"id":"2593822354","title":"泰恩康最新公告:全资子公司收到非那雄胺他达拉非胶囊药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2593822354","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593822354?lang=zh_cn&edition=full","pubTime":"2025-12-22 20:21","pubTimestamp":1766406084,"startTime":"0","endTime":"0","summary":"泰恩康(301263.SZ)公告称,公司全资子公司山东华铂凯盛生物科技有限公司收到国家药品监督管理局签发的非那雄胺他达拉非胶囊《药品注册证书》。该药品用于治疗男性良性前列腺增生,由非那雄胺和他达拉非组成,具有显著的临床优势和市场潜力。截至目前,非那雄胺他达拉非胶囊在国内尚无其他企业获得药品注册证书,华铂凯盛为国内首家获得药品注册证书的企业。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200030359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2592193577","title":"泰恩康(301263)披露控股股东、实际控制人部分股份解除质押公告,12月19日股价上涨2.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592193577","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592193577?lang=zh_cn&edition=full","pubTime":"2025-12-19 22:55","pubTimestamp":1766156142,"startTime":"0","endTime":"0","summary":"公司于近日发布公告称,控股股东、实际控制人孙伟文女士所持有的2,400,000股公司股份已于2025年12月18日办理了解除质押手续,占其所持股份比例3.62%,占公司总股本比例0.56%,质权人为渤海国际信托股份有限公司。截至公告披露日,孙伟文累计质押股份5,500,000股,占其持股比例8.31%。公告指出,相关股东资信状况良好,质押股份无强制平仓风险,不会对公司经营和治理产生实质性影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900040399.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772764533422,"stockEarnings":[{"period":"1week","weight":-0.0886},{"period":"1month","weight":-0.0811},{"period":"3month","weight":0.064},{"period":"6month","weight":-0.2077},{"period":"1year","weight":0.4839},{"period":"ytd","weight":-0.0028}],"compareEarnings":[{"period":"1week","weight":-0.0092},{"period":"1month","weight":0.01},{"period":"3month","weight":0.0527},{"period":"6month","weight":0.0777},{"period":"1year","weight":0.2294},{"period":"ytd","weight":0.0352}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"广东泰恩康医药股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"11961人(较上一季度增加9.32%)","perCapita":"25381股","listingDate":"2022-03-29","address":"广东省汕头市龙湖区泰山北路万吉南二街8号A幢","registeredCapital":"42549万元","survey":" 广东泰恩康医药股份有限公司的主营业务是代理运营及研发、生产、销售医药产品、医疗器械、卫生材料并提供医药技术服务与技术转让等。公司的主要产品是盐酸达泊西汀片、他达拉非片、枸橼酸西地那非口崩片、和胃整肠丸、沃丽汀、风油精、六味地黄丸、藿香正气丸、奥硝唑注射液。公司自主研发的“爱廷玖”盐酸达泊西汀片为首个国产PE用药,2020年8月正式投放市场,目前在达泊西汀院外渠道市场稳居头部地位,尤其在线下零售市场形成显著品牌优势。","listedPrice":19.93},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰恩康(301263)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰恩康(301263)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰恩康,301263,泰恩康股票,泰恩康股票老虎,泰恩康股票老虎国际,泰恩康行情,泰恩康股票行情,泰恩康股价,泰恩康股市,泰恩康股票价格,泰恩康股票交易,泰恩康股票购买,泰恩康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰恩康(301263)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰恩康(301263)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}